FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019168803> ?p ?o ?g. }

• W2019168803 endingPage "147" @default.
• W2019168803 startingPage "143" @default.
• W2019168803 abstract "SummaryCamurati-Engelmann disease (CED [MIM 131300]), or progressive diaphyseal dysplasia, is an autosomal dominant sclerosing bone dysplasia characterized by progressive bone formation along the periosteal and endosteal surfaces at the diaphyseal and metaphyseal regions of long bones and cranial hyperostosis, particularly at the skull base. The gene for CED, or its chromosomal localization, has not yet been identified. We performed a genomewide linkage analysis of two unrelated Japanese families with CED, in which a total of 27 members were available for this study; 16 of them were affected with the disease. Two-point linkage analysis revealed a maximum LOD score of 7.41 (recombination fraction .00; penetrance 1.00) for the D19S918 microsatellite marker locus. Haplotype analysis revealed that all the affected individuals shared a common haplotype observed, in each family, between D19S881 and D19S606, at chromosome 19q13.1-q13.3. These findings, together with a genetic distance among the marker loci, indicate that the CED locus can be assigned to a 15.1-cM segment between D19S881 and D19S606. Camurati-Engelmann disease (CED [MIM 131300]), or progressive diaphyseal dysplasia, is an autosomal dominant sclerosing bone dysplasia characterized by progressive bone formation along the periosteal and endosteal surfaces at the diaphyseal and metaphyseal regions of long bones and cranial hyperostosis, particularly at the skull base. The gene for CED, or its chromosomal localization, has not yet been identified. We performed a genomewide linkage analysis of two unrelated Japanese families with CED, in which a total of 27 members were available for this study; 16 of them were affected with the disease. Two-point linkage analysis revealed a maximum LOD score of 7.41 (recombination fraction .00; penetrance 1.00) for the D19S918 microsatellite marker locus. Haplotype analysis revealed that all the affected individuals shared a common haplotype observed, in each family, between D19S881 and D19S606, at chromosome 19q13.1-q13.3. These findings, together with a genetic distance among the marker loci, indicate that the CED locus can be assigned to a 15.1-cM segment between D19S881 and D19S606. Camurati-Engelmann disease (CED [MIM 131300]), or progressive diaphyseal dysplasia, is an osteosclerotic dysplasia characterized by symmetrical hyperostosis initiating at the diaphyses of the long tubular bones, usually of the femora or tibiae, and expanding to their metaphyses and to membranous bones. The hyperostosis of the skull base occasionally leads to cranial nerve palsy. The onset of the disease is often during early childhood and almost always at age <30 years. Radiographic abnormalities include diaphyseal cortical thickening, periosteal and endosteal sclerosis of the long bones, and basal skull sclerosis. Patients with CED have severe pain in the legs, muscle weakness, a waddling gait, and easy fatigability and occasionally suffer from systemic manifestations, such as anemia, leukopenia, or hepatosplenomegaly (Crisp and Brenton Crisp and Brenton, 1982Crisp AJ Brenton DP Engelmann's disease of bone—a systemic disorder?.Ann Rheum Dis. 1982; 41: 183-188Crossref PubMed Scopus (38) Google Scholar). No specific laboratory findings for the disease have been identified, although a raised erythrocyte-sedimentation rate, an increased level of serum alkaline phosphatase, increased urinary excretion of hydroxyproline, or a reduced level of hematocrit or hemoglobin have been reported in some patients (Hundley and Wilson Hundley and Wilson, 1973Hundley JD Wilson FC Progessive diaphyseal dysplasia: review of the literature and report of seven cases in one family.J Bone Joint Surg [Am]. 1973; 55: 461-474PubMed Google Scholar; Smith et al. Smith et al., 1977Smith R Walton RJ Corner BD Gordon IR Clinical and biochemical studies in Engelmann's disease (progressive diaphyseal dysplasia).Q J Med. 1977; 46: 273-294PubMed Google Scholar; Crisp and Brenton Crisp and Brenton, 1982Crisp AJ Brenton DP Engelmann's disease of bone—a systemic disorder?.Ann Rheum Dis. 1982; 41: 183-188Crossref PubMed Scopus (38) Google Scholar). Pollack et al. (Pollack et al., 1989Pollack S Naveh Y Katz R Immunological investigations in 2 families with progressive diaphyseal dysplasia.J Rheumatol. 1989; 16: 1259-1262PubMed Google Scholar) reported that all the patients examined by them had markedly elevated proportions of OKM1-positive mononuclear cells and that some of the healthy relatives also exhibited the same abnormality. Therapy with a prolonged low dosage of corticosteroid hormone is effective not only in relieving the pain but also in reversing the radiological findings, although the mechanism through which steroids act remains undefined (Minford et al Minford et al., 1981Minford AM Hardy GJ Forsythe WI Fitton JM Rowe VL Engelmann's disease and the effect of corticosteroids: a case report.J Bone Joint Surg [Br]. 1981; 63B: 597-600PubMed Google Scholar). Reported histopathological findings, although they are controversial, include altered bone cortex, with progressive active bone resorption as well as deposition (Rubin Rubin, 1964Rubin P Diaphyseal hyperplasias.in: In: Dynamic classification of bone dysplasias. Year Book Medical, Chicago1964: 325-349Google Scholar); the absence of osteoclasts in the bone lesions, which recovered after steroid treatment leading to increased bone absorption and secondary remodeling (Allen et al. Allen et al., 1970Allen DT Saunders AM Northway Jr, WH Williams GF Schafer IA Corticosteroids in the treatment of Engelmann's disease: progressive diaphyseal dysplasia.Pediatrics. 1970; 46: 523-531PubMed Google Scholar); and thickening of the blood-vessel wall in the bone (Rubin Rubin, 1964Rubin P Diaphyseal hyperplasias.in: In: Dynamic classification of bone dysplasias. Year Book Medical, Chicago1964: 325-349Google Scholar) and skeletal muscles (Yoshioka et al. Yoshioka et al., 1980Yoshioka H Mino M Kiyosawa N Hirasawa Y Morikawa Y Kasubuchi Y Kusunoki T Muscular changes in Engelmann's disease.Arch Dis Child. 1980; 55: 716-719Crossref PubMed Scopus (15) Google Scholar; Naveh et al. Naveh et al., 1985Naveh Y Ludatshcer R Alon U Sharf B Muscle involvement in progressive diaphyseal dysplasia.Pediatrics. 1985; 76: 944-949PubMed Google Scholar). Diagnosis is based on these clinical, radiographic, and/or pathological manifestations. More than 100 patients with CED have been reported in the literature, and the prevalence of CED is estimated to be <1/1 million (Wynne-Davies et al. Wynne-Davies et al., 1985Wynne-Davies R Hall CM Apley AG Engelmann's disease.in: In: Atlas of skeletal dysplasias. Churchill Livingstone, Edinburgh1985: 488-494Google Scholar). Both sporadic and familial cases have been described. In familial cases, the disease is inherited in an autosomal dominant mode with incomplete penetrance and variable expression (Sparkes and Graham Sparkes and Graham, 1972Sparkes RS Graham CB Camurati-Engelmann disease: genetics and clinical manifestations with a review of the literature.J Med Genet. 1972; 9: 73-85Crossref PubMed Scopus (69) Google Scholar). Here we report the result of a genetic linkage analysis of two unrelated Japanese families with CED. Two unrelated Japanese families (families 1 and 2) were analyzed in the present study. A total of 27 members of the two families agreed to participate in the present study, with written informed consent. Of the 27 members, 16 were diagnosed as having CED (fig. 1), on the basis of clinical and radiographic findings—that is, continuous disabling pain in the legs, muscle weakness with waddling gait, diaphyseal cortical fusiform thickening, and periosteal and endosteal sclerosis of the long bones. Detailed clinical data on affected members of family 1 have been reported elsewhere (Makita et al., Makita et al., in pressMakita Y, Nishimura G, Ikegawa S, Ishii T, Ito Y, Okuno A. Intrafamilial phenotypic variability in Engelmann disease (ED): are ED and Ribbing disease the same entity? Am J Med Genet (in press)Google Scholar). The proband in family 2 (I-3; see fig. 1) was a 48-year-old woman with complaints of upper- and lower-limb pain, easy fatigability, muscle weakness, and waddling gait. Onset of her disease was at age 3 years. The findings of radiographic survey and 99mTc-MDP bone scintigraphy were consistent with CED. Three of her four children are also affected with CED (fig. 1). Genomic DNA samples were collected from the 27 available individuals in the two families. Highly polymorphic microsatellite markers were chosen from the Généthon database (Dib et al. Dib et al., 1996Dib C Fauré S Fizames C Samson D Drouot N Vignal A Millasseau P et al.A comprehensive genetic map of the human genome based on 5,264 microsatellites.Nature. 1996; 380: 152-154Crossref PubMed Scopus (2669) Google Scholar), and their corresponding primer sets were synthesized. The forward primer of each set was labeled with fluorescent dye (Cy5; Pharmacia Biotech), and the reverse primer was not labeled. For the chromosomal assignment of the disease locus, we adopted a two-step analysis. In the first step, we performed a genomewide linkage analysis using markers distributed across the genome that were separated by an average distance of ∼10 cM. When preliminary data for assignment to a chromosomal region were obtained, we analyzed additional markers to confirm the linkage and to delimit the CED critical region (CEDR) (fig. 1). PCR amplification was performed in a 12.5-μl reaction mixture containing 50 ng of genomic DNA, 1–3 mM MgCl2, 0.2 mM of each deoxynucleotide triphosphate, 0.5 U of DNA polymerase (AmpliTaq Gold; PE Biosystems), and 12.5 pmol of each primer. PCR conditions consisted of an initial denaturation at 94°C for 10 min; 40 cycles of denaturation at 94°C for 30 s, annealing at 48–58°C for 30 s, and extension at 72°C for 30 s; and final extension at 72°C for 10 min. PCR products were resolved by electrophoresis on 6% polyacrylamide DNA sequencing gel, by use of an automated sequencer (ALFexpress; Pharmacia Biotech). Electrophoretic patterns were analyzed by computer software (Fragment Manager; Pharmacia Biotech), to determine the genotypes of the family members. Two-point linkage analysis was performed by the computer program MLINK of the FASTLINK software, version 4.0P (Lathrop et al. Lathrop et al., 1984Lathrop GM Lalouel JM Julier C Ott J Strategies for multilocus linkage analysis in humans.Proc Natl Acad Sci USA. 1984; 81: 3443-3446Crossref PubMed Scopus (2173) Google Scholar; Cottingham et al. Cottingham et al., 1993Cottingham Jr, RW Idury RM Schäffer AA Faster sequential genetic linkage computations.Am J Hum Genet. 1993; 53: 252-263PubMed Google Scholar; Schäffer et al. Schaffer et al., 1994Schaffer AA Gupta SK Shriram K Cottingham Jr, RW Avoiding recomputation in linkage analysis.Hum Hered. 1994; 44: 225-237Crossref PubMed Scopus (610) Google Scholar), under the assumption that CED in the two families is inherited in an autosomal dominant mode, with a disease-gene frequency of .000001 (Wynne-Davies et al. Wynne-Davies et al., 1985Wynne-Davies R Hall CM Apley AG Engelmann's disease.in: In: Atlas of skeletal dysplasias. Churchill Livingstone, Edinburgh1985: 488-494Google Scholar). Equal allele frequencies were used for all marker loci. However, the allele frequency for each of five markers (D19S422, D19S223, D19S918, D19S902, and D19S606) around the CEDR was calculated in 80 chromosomes from unrelated healthy Japanese individuals. Since samples were collected earlier from family 1 and since it is larger than family 2, we first undertook a genomewide search in family 1. A maximum two-point LOD score (Zmax=6.20 at recombination fraction [θ] .00) was obtained at the D19S918 locus when penetrance (p) was assumed to be 1.0. We chose 23 additional markers (16 markers centromeric to and 7 telomeric to D19S918) that are located around D19S918, to analyze family 1. Haplotype analysis of family 1 demonstrated that all the affected members had a common haplotype between D19S881 and D19S606, including 15 markers (fig. 1). Recombinations had occurred four times in three affected members: one between D19S422 and D19S223 in individual II-2, one between D19S219 and D19S606 in II-10, and two (double recombination), between D19S414 and D19S570 and between D19S881 and D19S211, in III-9 (fig. 1). Thus, most of the region associated with CED lies between D19S881 and D19S606. We then extended the analysis with the same markers to family 2 and confirmed a linkage of the disease to the same chromosomal region between D19S881 and D19S606 (fig. 1). There was one recombination between D19S606 and D19S867 in individual II-3 in this family. Results for this family, however, did not allow us to narrow the linked segment. The two-point Zmax calculated for the two families was 7.41, for D19S918, at θ=.00 (p=1.00) (table 1). In light of the genetic distance between the markers used, the CEDR lies in a 15.1-cM segment between D19S881 and D19S606, at 19q13.1-q13.3 (Genome Database [Japan]; Human Genome Resources) (fig. 1).Table 1Two-Point LOD Scores of CED in the Two Families, at Representative Marker Loci at 19q13.1-q13.3, with Representative p ValuesLOD Score at θ=Locus andp.00.001.05.1.15.2D19S422: 1.0−∞−3.38.01.50.68.71 .8−7.13−3.52−.17.31.49.54D19S223: 1.03.603.593.252.882.502.11 .83.133.122.812.482.131.79D19S211: 1.05.445.445.144.734.273.75 .85.035.034.654.223.773.28D19S913: 1.04.924.914.653.993.492.97 .84.374.363.953.503.052.58D19S408: 1.04.224.224.083.813.453.03 .84.094.093.803.463.082.67D19S217: 1.05.845.845.364.824.243.62 .85.185.184.704.193.653.08D19S918: 1.07.417.396.776.105.444.67 .86.556.545.965.354.724.06D19S219: 1.04.254.243.903.523.122.68 .83.943.933.593.232.832.41D19S902: 1.02.542.542.322.071.801.52 .82.282.272.061.821.581.33D19S606: 1.0−∞.231.681.711.601.41 .8−2.34−.021.431.471.371.21 Open table in a new tab It has been documented that CED is inherited in an autosomal dominant fashion with incomplete penetrance and variable expressivity (Sparkes and Graham Sparkes and Graham, 1972Sparkes RS Graham CB Camurati-Engelmann disease: genetics and clinical manifestations with a review of the literature.J Med Genet. 1972; 9: 73-85Crossref PubMed Scopus (69) Google Scholar). The two families examined in the present study showed complete penetrance, although expressivity was very variable in family 1. In family 1, 5 of the 12 affected members had clinical manifestations milder than those seen in the other 7, and the age at disease onset among these 12 members varied from age 3 years to the late 20s. An 8-year-old boy (III-2) and a 25-year-old man (III-7) in the family did not present any clinical symptoms of CED (Makita et al., Makita et al., in pressMakita Y, Nishimura G, Ikegawa S, Ishii T, Ito Y, Okuno A. Intrafamilial phenotypic variability in Engelmann disease (ED): are ED and Ribbing disease the same entity? Am J Med Genet (in press)Google Scholar) but were found to have both periosteal sclerosis of the fibula and the disease-associated haplotype (fig. 1). Thus, penetrance was complete in this family, when an extensive radiographic survey was performed in the two asymptomatic patients. The highly variable expressivity of the disorder may explain why “incomplete penetrance” has been proposed, and why “autosomal recessive inheritance” has been considered in some families (Hundley and Wilson Hundley and Wilson, 1973Hundley JD Wilson FC Progessive diaphyseal dysplasia: review of the literature and report of seven cases in one family.J Bone Joint Surg [Am]. 1973; 55: 461-474PubMed Google Scholar). Clybouw et al. (Clybouw et al., 1994Clybouw C Desmyttere S Bonduelle M Piepsz A Camurati-Engelmann disease: contribution of bone scintigraphy to genetic counseling.Genet Couns. 1994; 5: 195-198PubMed Google Scholar) reported a family in which the mother of a patient with CED had no abnormal clinical findings but showed, on 99mTc-scintigraphy, increased osteoblastic activity in the diaphyseal portions of almost all long bones, and they suggested the necessity of detailed radiographic examinations to diagnose CED. Phenotypes of five affected members of family 1 were reminiscent of Ribbing disease, as suggested by Makita et al. (Makita et al., in pressMakita Y, Nishimura G, Ikegawa S, Ishii T, Ito Y, Okuno A. Intrafamilial phenotypic variability in Engelmann disease (ED): are ED and Ribbing disease the same entity? Am J Med Genet (in press)Google Scholar). The region of 19q13.1-q13.3 defined as the CEDR is a gene-rich region to which several genes, skeletal tissue–derived expressed-sequence tags, or bone dysplasia–related disease loci have been mapped. Among them, the genes for calmodulin 3 (CALM3) (Berchtold et al. Berchtold et al., 1993Berchtold MW Egli R Rhyner JA Hameister H Strehler EE Localization of the human bona fide calmodulin genes CALM1, CALM2, and CALM3 to chromosome 14q23-q31, 2p21.1-21.3 and 19q13.2-q13.3.Genomics. 1993; 16: 461-465Crossref PubMed Scopus (70) Google Scholar), zinc-finger protein 36 (ZFP36) (Taylor et al. Taylor et al., 1991Taylor GA Lai WS Oakey RJ Seldin MF Shows TB Eddy Jr, RL Blackshear PJ The human TTP protein: sequence, alignment with related proteins, and chromosomal localization of the mouse and human genes.Nucleic Acids Res. 1991; 19: 3454Crossref PubMed Scopus (82) Google Scholar), and transforming growth-factor beta 1 (TGFB1) (Fujii et al. Fujii et al., 1986Fujii D Brissenden JE Derynck R Francke U Transforming growth factor beta gene maps to human chromosome 19 long arm and mouse chromosome 7.Somat Cell Mol Genet. 1986; 12: 281-288Crossref PubMed Scopus (178) Google Scholar) merit comments. CALM3 encodes a calcium-modulated protein; ZNF36 is the gene for a zinc-finger protein, and ZNF36-deficient mice are born as normal neonates but soon develop a complex syndrome of inflammatory arthritis, dermatitis, cachexia, autoimmunity, and myeloid hyperplasia; and TGFB1 encodes a member of the TGF-β superfamily. Since a high level of the TGFB1 message appears in both osteoblasts and osteoclasts of the developing bone, as well as in the periosteal fibroblasts and bone marrow cells, TGFB1 may play an important role in postnatal bone development (Sandberg et al. Sandberg et al., 1988aSandberg M Autio-Harmainen H Vuorio E Localization of the expression of types I, III, and IV collagen, TGF-b1 and c-fos genes in developing human calvarial bones.Dev Biol. 1988; 130: 324-334Crossref PubMed Scopus (85) Google Scholar,Sandberg et al., 1988bSandberg M Vuorio T Hirvonen H Alitalo K Vuorio E Enhanced expression of TGF-b and c-fos mRNAs in the growth factor plates of developing human long bones.Development. 1988; 102: 461-470PubMed Google Scholar). Tgfb1 knockout (Tgfb1−/−) mice show decreased mineral content in the proximal tibial metaphyses—as evidenced in the width of the tibial growth plate and the longitudinal growth rate—as well as various systemic manifestations, although the heterozygous (Tgfb1 +/−) mice show normal bone development (Geiser et al. Geiser et al., 1998Geiser AG Zeng QQ Sato M Helvering LM Hirano T Turner CH Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene.Bone. 1998; 23: 87-93Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). It remains to be seen whether any of these genes, especially TGFB1, are causally related to CED. We express our gratitude to Dr. Kenji Hisa, for providing family 2, and to Prof. Yusuke Nakamura, for providing primers for CA-repeat markers. This study was supported in part by Grants-in-Aid for Scientific Research (08307019 and 10770489), from the Ministry of Education, Science, Sport and Culture, and by a Grant-in-Aid for Human Genome Analysis, from the Ministry of Health and Welfare of Japan. Erratum et al.The American Journal of Human GeneticsFebruary, 2000In BriefIn the article “Genetic Mapping of the Camurati-Engelmann Disease Locus to Chromosome 19q13.1-q13.3,” by Ghadami et al., published in the January 2000 issue of the Journal (66:143–147), an error occurred in the second paragraph of the Discussion section: in lines 9 and 10, the gene designation should be “ZFP36,” as in line 6 of the same paragraph (not “ZNF36”). Full-Text PDF Open Archive" @default.
• W2019168803 created "2016-06-24" @default.
• W2019168803 creator A5005242725 @default.
• W2019168803 creator A5008586011 @default.
• W2019168803 creator A5015693631 @default.
• W2019168803 creator A5034461584 @default.
• W2019168803 creator A5046338027 @default.
• W2019168803 creator A5052116795 @default.
• W2019168803 creator A5059018147 @default.
• W2019168803 creator A5063192675 @default.
• W2019168803 creator A5064984742 @default.
• W2019168803 creator A5070780262 @default.
• W2019168803 creator A5072772963 @default.
• W2019168803 date "2000-01-01" @default.
• W2019168803 modified "2023-10-11" @default.
• W2019168803 title "Genetic Mapping of the Camurati-Engelmann Disease Locus to Chromosome 19q13.1-q13.3" @default.
• W2019168803 cites W1508444814 @default.
• W2019168803 cites W1538524809 @default.
• W2019168803 cites W1557395568 @default.
• W2019168803 cites W1965265115 @default.
• W2019168803 cites W1965437277 @default.
• W2019168803 cites W2017428806 @default.
• W2019168803 cites W2018895281 @default.
• W2019168803 cites W2022841155 @default.
• W2019168803 cites W2030214728 @default.
• W2019168803 cites W2036851084 @default.
• W2019168803 cites W2045867556 @default.
• W2019168803 cites W2061833150 @default.
• W2019168803 cites W2084772014 @default.
• W2019168803 cites W2104318782 @default.
• W2019168803 cites W2116753154 @default.
• W2019168803 cites W2124937939 @default.
• W2019168803 cites W2397840073 @default.
• W2019168803 cites W2410567289 @default.
• W2019168803 cites W2411688878 @default.
• W2019168803 cites W2413344011 @default.
• W2019168803 cites W2415125429 @default.
• W2019168803 cites W4205739706 @default.
• W2019168803 doi "https://doi.org/10.1086/302728" @default.
• W2019168803 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1288319" @default.
• W2019168803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10631145" @default.
• W2019168803 hasPublicationYear "2000" @default.
• W2019168803 type Work @default.
• W2019168803 sameAs 2019168803 @default.
• W2019168803 citedByCount "68" @default.
• W2019168803 countsByYear W20191688032012 @default.
• W2019168803 countsByYear W20191688032013 @default.
• W2019168803 countsByYear W20191688032014 @default.
• W2019168803 countsByYear W20191688032015 @default.
• W2019168803 countsByYear W20191688032016 @default.
• W2019168803 countsByYear W20191688032017 @default.
• W2019168803 countsByYear W20191688032018 @default.
• W2019168803 countsByYear W20191688032019 @default.
• W2019168803 countsByYear W20191688032020 @default.
• W2019168803 countsByYear W20191688032021 @default.
• W2019168803 countsByYear W20191688032022 @default.
• W2019168803 crossrefType "journal-article" @default.
• W2019168803 hasAuthorship W2019168803A5005242725 @default.
• W2019168803 hasAuthorship W2019168803A5008586011 @default.
• W2019168803 hasAuthorship W2019168803A5015693631 @default.
• W2019168803 hasAuthorship W2019168803A5034461584 @default.
• W2019168803 hasAuthorship W2019168803A5046338027 @default.
• W2019168803 hasAuthorship W2019168803A5052116795 @default.
• W2019168803 hasAuthorship W2019168803A5059018147 @default.
• W2019168803 hasAuthorship W2019168803A5063192675 @default.
• W2019168803 hasAuthorship W2019168803A5064984742 @default.
• W2019168803 hasAuthorship W2019168803A5070780262 @default.
• W2019168803 hasAuthorship W2019168803A5072772963 @default.
• W2019168803 hasBestOaLocation W20191688031 @default.
• W2019168803 hasConcept C104317684 @default.
• W2019168803 hasConcept C122735190 @default.
• W2019168803 hasConcept C30481170 @default.
• W2019168803 hasConcept C54355233 @default.
• W2019168803 hasConcept C84597430 @default.
• W2019168803 hasConcept C86803240 @default.
• W2019168803 hasConceptScore W2019168803C104317684 @default.
• W2019168803 hasConceptScore W2019168803C122735190 @default.
• W2019168803 hasConceptScore W2019168803C30481170 @default.
• W2019168803 hasConceptScore W2019168803C54355233 @default.
• W2019168803 hasConceptScore W2019168803C84597430 @default.
• W2019168803 hasConceptScore W2019168803C86803240 @default.
• W2019168803 hasFunder F4320320912 @default.
• W2019168803 hasFunder F4320321945 @default.
• W2019168803 hasIssue "1" @default.
• W2019168803 hasLocation W20191688031 @default.
• W2019168803 hasLocation W20191688032 @default.
• W2019168803 hasLocation W20191688033 @default.
• W2019168803 hasLocation W20191688034 @default.
• W2019168803 hasOpenAccess W2019168803 @default.
• W2019168803 hasPrimaryLocation W20191688031 @default.
• W2019168803 hasRelatedWork W1828691184 @default.
• W2019168803 hasRelatedWork W1994389554 @default.
• W2019168803 hasRelatedWork W2003440365 @default.
• W2019168803 hasRelatedWork W2008510086 @default.
• W2019168803 hasRelatedWork W2071369380 @default.
• W2019168803 hasRelatedWork W2074700305 @default.
• W2019168803 hasRelatedWork W2116536724 @default.
• W2019168803 hasRelatedWork W2145533817 @default.

• next